Tested 212Pb imaging drug for certain advanced GRPR tumors
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older with an advanced or metastatic GRPR-expressing solid tumor (specific cancer types listed).
- You have tried at least 2 prior systemic treatments (except recurrent glioblastoma).
- You can sign informed consent and you are able to attend required scans and study visits.
- Scans must show the drug target in at least one measurable spot (or specific bone-uptake rules for prostate cancer).
- Your general health scores are usually good (ECOG 0–1; ECOG 2 only sometimes).
- Your blood counts and organ tests (bone marrow, liver, kidneys) must be within required lab ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests [212Pb]Pb-ADVC001, a radiotherapy-like cancer treatment, in people with advanced prostate cancer that shows up on a special PSMA scan. It aims to find the safest dose and see whether it helps shrink or control metastatic cancer.
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
This early-phase study tests a new imaging agent that may help see certain solid tumors (like brain cancer or pancreatic cancer) more clearly. You will receive a single injection of a radioactive tracer, then have several scans over a few days to see where the tracer goes and how long it stays.
This trial tests an experimental radioactive drug that targets a protein called PSMA found on prostate cancer cells. It aims to see if this drug is safe and can shrink tumors in men with advanced prostate cancer that has not responded to hormone therapy or chemotherapy.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.